Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival.

Weichert W, Denkert C, Burkhardt M, Gansukh T, Bellach J, Altevogt P, Dietel M, Kristiansen G.

Clin Cancer Res. 2005 Sep 15;11(18):6574-81.

2.

ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival.

Weichert W, Knösel T, Bellach J, Dietel M, Kristiansen G.

J Clin Pathol. 2004 Nov;57(11):1160-4.

3.

CD24 expression is a new prognostic marker in breast cancer.

Kristiansen G, Winzer KJ, Mayordomo E, Bellach J, Schlüns K, Denkert C, Dahl E, Pilarsky C, Altevogt P, Guski H, Dietel M.

Clin Cancer Res. 2003 Oct 15;9(13):4906-13.

4.

CD24 expression is a poor prognostic marker in endometrial carcinoma.

Karahan N, Güney M, Oral B, Kapucuoglu N, Mungan T.

Eur J Gynaecol Oncol. 2006;27(5):500-4.

PMID:
17139987
5.

Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors.

Choi YL, Kim SH, Shin YK, Hong YC, Lee SJ, Kang SY, Ahn G.

Gynecol Oncol. 2005 May;97(2):379-86.

PMID:
15863133
6.

Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times.

Kristiansen G, Jacob J, Buckendahl AC, Grützmann R, Alldinger I, Sipos B, Klöppel G, Bahra M, Langrehr JM, Neuhaus P, Dietel M, Pilarsky C.

Clin Cancer Res. 2006 Nov 1;12(21):6444-51.

7.

CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer.

Kristiansen G, Pilarsky C, Pervan J, Stürzebecher B, Stephan C, Jung K, Loening S, Rosenthal A, Dietel M.

Prostate. 2004 Feb 1;58(2):183-92.

PMID:
14716744
8.

14-3-3sigma expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients.

Perathoner A, Pirkebner D, Brandacher G, Spizzo G, Stadlmann S, Obrist P, Margreiter R, Amberger A.

Clin Cancer Res. 2005 May 1;11(9):3274-9.

9.

GABARAP is overexpressed in colorectal carcinoma and correlates with shortened patient survival.

Miao Y, Zhang Y, Chen Y, Chen L, Wang F.

Hepatogastroenterology. 2010 Mar-Apr;57(98):257-61.

PMID:
20583424
10.

Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis.

Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H.

Clin Cancer Res. 2005 Feb 1;11(3):1154-9.

11.

Expression of CD24 in clear cell renal cell carcinoma and its prognostic significance.

Lee HJ, Kim DI, Kwak C, Ku JH, Moon KC.

Urology. 2008 Sep;72(3):603-7. doi: 10.1016/j.urology.2008.01.061. Epub 2008 Apr 2.

PMID:
18384848
12.

Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma.

Chou YY, Jeng YM, Lee TT, Hu FC, Kao HL, Lin WC, Lai PL, Hu RH, Yuan RH.

Ann Surg Oncol. 2007 Oct;14(10):2748-58. Epub 2007 Aug 7.

PMID:
17680316
13.

Role of CD24 protein in predicting metastatic potential of uterine cervical squamous cell carcinoma in patients treated with radiotherapy.

Kwon GY, Ha H, Ahn G, Park SY, Huh SJ, Park W.

Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1150-6. Epub 2007 Aug 9.

PMID:
17692475
14.

Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients.

Ottaiano A, Franco R, Aiello Talamanca A, Liguori G, Tatangelo F, Delrio P, Nasti G, Barletta E, Facchini G, Daniele B, Di Blasi A, Napolitano M, Ieranò C, Calemma R, Leonardi E, Albino V, De Angelis V, Falanga M, Boccia V, Capuozzo M, Parisi V, Botti G, Castello G, Vincenzo Iaffaioli R, Scala S.

Clin Cancer Res. 2006 May 1;12(9):2795-803.

15.

CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.

Bircan S, Kapucuoglu N, Baspinar S, Inan G, Candir O.

Pathol Res Pract. 2006;202(8):569-76. Epub 2006 Jul 7.

PMID:
16828238
16.

Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.

Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, Werner ER, Werner-Felmayer G, Weiss HG, Göbel G, Margreiter R, Königsrainer A, Fuchs D, Amberger A.

Clin Cancer Res. 2006 Feb 15;12(4):1144-51.

17.

Intense cytoplasmic ezrin immunoreactivity predicts poor survival in colorectal cancer.

Elzagheid A, Korkeila E, Bendardaf R, Buhmeida A, Heikkilä S, Vaheri A, Syrjänen K, Pyrhönen S, Carpén O.

Hum Pathol. 2008 Dec;39(12):1737-43. doi: 10.1016/j.humpath.2008.04.020. Epub 2008 Aug 12.

PMID:
18701134
18.

Prognostic value of immunohistochemical estimation of CD24 and Ki67 expression in cisplatin and paclitaxel treated ovarian carcinoma patients.

Surowiak P, Materna V, Kłak K, Spaczyński M, Dietel M, Kristiansen G, Lage H, Zabel M.

Pol J Pathol. 2005;56(2):69-74.

PMID:
16092668
19.

CD24 shows early upregulation and nuclear expression but is not a prognostic marker in colorectal cancer.

Ahmed MA, Al-Attar A, Kim J, Watson NF, Scholefield JH, Durrant LG, Ilyas M.

J Clin Pathol. 2009 Dec;62(12):1117-22. doi: 10.1136/jcp.2009.069310.

PMID:
19946098
20.

Cytoplasmic c-erbB-2 protein expression correlates with survival in Dukes' B colorectal carcinoma.

Kay EW, Mulcahy H, Walsh CB, Leader M, O'Donoghue D.

Histopathology. 1994 Nov;25(5):455-61.

PMID:
7868086

Supplemental Content

Support Center